« Return to News | CROs/Service Providers | Drug Sponsors

Aptuit and GSK extend strategic partnership

Monday, November 19, 2012 09:50 AM

Aptuit, a pharmaceutical services company, has reached an agreement on a multi-year extension of its strategic partnership with global healthcare company GlaxoSmithKline (GSK) for dedicated drug development work at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The Verona site—formerly known as GSK’s Medicines Research Centre—was acquired by Aptuit from GSK in 2010.

"This multi-year extension of our partnership with GSK reaffirms that our Verona site continues to deliver scientific excellence that is recognized by our customers,” said Timothy C. Tyson, chairman, Aptuit. “Since we finalized our original agreement with GSK in 2010, we have successfully transformed the Verona site from a pharmaceutical research center to a world-class drug discovery and development outsourcing capability."

Tyson explained that during the two years since the Verona site became part of Aptuit it has effectively transitioned to a lean, flexible, customer-focused pharmaceutical services operation. To date, the Verona site has had approximately 50 successful audits and has delivered work for more than 100 clients.

“Aptuit initiatives in Verona, such as Lean Six Sigma, are resulting in productivity benefits across our business lines,” said Tyson. “The high level of quality and regulatory compliance demonstrated in our work has been noticeable to the more than 200 customers who have visited the site since 2010."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013
Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings
Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving
Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.